Nikola Corporation

Nikola Corporation (NASDAQ: NKLA) designs and manufactures zero-emission battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, components, energy storage systems, and hydrogen station infrastructure.

Key Highlights

• The company did not generate any revenue during Q3FY21 and 9MFY21.
• Its net loss for Q3FY21 (ended September 30, 2021) increased to USD 267.6 million from USD 79.7 million reported in Q3FY20.
• On July 29, 2021, the US Department of Justice announced that NKLA's founder, Trevor Milton, was indicted for making false and misleading statements to investors from November 2019 to September 2020.
• The stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels and its RSI Index is at 43.74.
• It is currently trading close to the lower end of its 52-week range of USD 9.02 to USD 30.40.
• NKLA's stock price corrected 40.37% and 44.87% in the past six and twelve months, respectively.

Technical Price Chart (as of December 08, 2021). Analysis by Kalkine

Conclusion: Considering the company's loss-making status, fraudulent activities, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 10.43, up 1.36%, as of December 08, 2021, at 12:13 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Selecta Biosciences Inc.

Selecta Biosciences Inc. (NASDAQ: SELB) operates as a clinical-stage biotechnology company that develops tolerogenic therapies that selectively mitigate unwanted immune responses using its ImmTOR platform. It has various proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases.

Key Highlights

• SELB generated USD 24.4 million in revenue during Q3FY21 (ended September 30, 2021), compared to USD 4.6 million reported in Q3FY20.
• Its Q3FY21 net loss amounted to USD 17.9 million vs. USD 9.7 million reported in Q3FY20, owing to higher R&D and general & administrative expenses.
• It reported negative operating margins in Q3FY21, with EBITDA, operating and net margins of 6.7%, 8.1% and 73.3%, respectively.
• The stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels and its RSI Index is at 43.67.
• It is leaning towards the lower end of its 52-week range of USD 2.67 to USD 5.70.
• SELB's stock fell 32.59% in the past six months.

Technical Price Chart (as of December 08, 2021). Analysis by Kalkine

Conclusion: Considering the technical indicators, disappointing profit margins and lackluster fundamentals, we recommend an "Avoid" rating on the stock at the current price of USD 3.175, down 0.16%, as of December 08, 2021, at 11:52 AM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc. (NYSE: AMPE) is a biopharmaceutical company engaged in advancing immunology-based therapies for treating common inflammatory conditions with limited treatment options. Its primary product is Ampion, which will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act (BPCIA).

Key Highlights

• AMPE has not generated any revenues to date.
• Its Q3FY21 net loss amounted to USD 3.6 million vs. USD 3.4 million reported in Q3FY20, representing a diluted loss per share of USD 0.02.
• It reported negative operating margins in Q3FY21, with EBITDA, operating and net margins of 6.7%, 8.1% and 73.3%, respectively.
• The stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels and its RSI Index is at 35.60.
• It is leaning towards the lower end of its 52-week range of USD 0.92 to USD 2.98.
• AMPE's stock fell 41.61% in the past six months.

Technical Price Chart (as of December 08, 2021). Analysis by Kalkine

Conclusion: Considering the technical indicators, disappointing profit margins and lackluster fundamentals, we recommend an "Avoid" rating on the stock at the current price of USD 3.175, down 0.16%, as of December 08, 2021, at 11:52 AM ET.

*The reference data in this report has been partly sourced from REFINITIV.